Abstract
Chromosome locus 11q13 is frequently amplified in several of solid tumors including non-small cell lung cancer (NSCLC). It was reported that the frequent amplification of chromosome 11q13 in solid tumors were associated with clinical worsen response to immune checkpoint inhibitors or even hyper-progression disease (HPD). However, the underlying mechanism for the association was still ambiguous. Herein, based on data of 10582 Chinse patients with NSCLC, we analyzed characteristics of FGF3/4/19, CCND1 which located in chromosome 11q13, and explored the potential mechanism HPD related to the amplification in chromosome 11q13 in NSCLC patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
